Cardiac differentiation of human pluripotent stem cells in scalable suspension culture.
Henning KempfChristina KroppRuth OlmerUlrich MartinRobert ZweigerdtPublished in: Nature protocols (2015)
Cardiomyocytes (CMs) generated from human pluripotent stem cells (hPSCs) are a potential cell source for regenerative therapies, drug discovery and disease modeling. All these applications require a routine supply of relatively large quantities of in vitro-generated CMs. This protocol describes a suspension culture-based strategy for the generation of hPSC-CMs as cell-only aggregates, which facilitates process development and scale-up. Aggregates are formed for 4 d in hPSC culture medium followed by 10 d of directed differentiation by applying chemical Wnt pathway modulators. The protocol is applicable to static multiwell formats supporting fast adaptation to specific hPSC line requirements. We also demonstrate how to apply the protocol using stirred tank bioreactors at a 100-ml scale, providing a well-controlled upscaling platform for CM production. In bioreactors, the generation of 40-50 million CMs per differentiation batch at >80% purity without further lineage enrichment can been achieved within 24 d.
Keyphrases
- pluripotent stem cells
- single cell
- drug discovery
- cell therapy
- randomized controlled trial
- stem cells
- mesenchymal stem cells
- wastewater treatment
- endothelial cells
- small molecule
- left ventricular
- cell proliferation
- high throughput
- clinical practice
- atrial fibrillation
- risk assessment
- induced pluripotent stem cells
- human health
- anaerobic digestion